67 research outputs found

    Heat sealable, flame and abrasion resistant coated fabric

    Get PDF
    Flame retardant, abrasion resistant elastomeric compositions are comprised of thermoplastic polyurethane polymer and flame retarding amounts of a filler selected from decabromodiphenyloxide and antimony oxide in a 3:1 weight ratio, and decabromodiphenyloxide, antimony oxide, and ammonium polyphosphate in a 3:1:3 weight ratio respectively. Coated fabrics employing such elastomeric compositions as coating film are flexible, lightweight, and air impermeable and can be made using heat or dielectric sealing procedures

    Heat resistant protective hand covering

    Get PDF
    A heat-resistant aromatic polyamide fiber is described. The outer surface of the shell is coated with a fire-resistant elastomer and liner. Generally conforming and secured to the shell and disposed inwardly of the shell, the liner is made of a felt fabric of temperature-resistant aromatic polymide fiber

    Zur mikroskopischen Untersuchung des Zimtes

    No full text

    Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study

    Get PDF
    BACKGROUND: Currently there is no effective treatment available to retard cyst growth and to prevent the progression to end-stage renal failure in patients with autosomal dominant polycystic kidney disease (ADPKD). Evidence has recently been obtained from animal experiments that activation of the mammalian target of rapamycin (mTOR) signaling pathway plays a crucial role in cyst growth and renal volume expansion, and that the inhibition of mTOR with rapamycin (sirolimus) markedly slows cyst development and renal functional deterioration. Based on these promising results in animals we have designed and initiated the first randomized controlled trial (RCT) to examine the effectiveness, safety and tolerability of sirolimus to retard disease progression in ADPKD. METHOD/DESIGN: This single center, randomised controlled, open label trial assesses the therapeutic effect, safety and tolerability of the mTOR inhibitor sirolimus (Rapamune) in patients with autosomal dominant polycystic kidney disease and preserved renal function. The primary outcome will be the inhibition of kidney volume growth measured by magnetic resonance imaging (MRI) volumetry. Secondary outcome parameters will be preservation of renal function, safety and tolerability of sirolimus. DISCUSSION: The results from this proof-of-concept RCT will for the first time show whether treatment with sirolimus effectively retards cyst growth in patients with ADPKD
    • …
    corecore